Vaccines for amoebiasis: barriers and opportunities.

Vaccines for amoebiasis: barriers and opportunities. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Vaccines for amoebiasis: barriers and opportunities. Abstract Text:

S L Stanley,

Amoebiasis, infection by the protozoan parasite Entamoeba histolytica, remains a global health problem, despite the availability of effective treatment. While improved sanitation could lead to the eradication of this disease, it is unlikely that this will occur worldwide in the foreseeable future; thus alternative measures must be pursued. One approach is to develop a vaccine to prevent this deadly disease. Clinical studies indicate that mucosal immunity may provide some protection against recurrent intestinal infection with E. histolytica, but there is no clear evidence that protective immunity develops after amoebic liver abscess. Over the past decade, progress in vaccine development has been facilitated by new animal models that allow better testing of potential vaccine candidates and the application of recombinant technology to vaccine design. Oral vaccines and DNA-based vaccines have been successfully tested in animals models for immunogenicity and efficacy. There has been significant progress on a number of fronts, but there are unanswered questions regarding the effectiveness of immune responses in preventing disease in man and, as yet, no testing of any of these vaccines in humans has been performed. In addition, there are strong economic barriers to developing an amoebiasis vaccine and questions about how and where an effective vaccine would be utilized.

Vaccines for amoebiasis: barriers and opportunities. Publishing Authors By Initials

SL Stanley,

For similar proteins: recombinant proteins: vaccines, synthetic research abstracts see: proteins: recombinant proteins: vaccines, synthetic research

PUBMED ID PMID:

MEDLINE DATE:

Vaccines for amoebiasis: barriers and opportunities. Journal Published:

PUBLICATION TYPE: Review

Journal: Parasitology

VOLUME: 133 Suppl

Page Numbers: S81-6

Journal Abbreviation: Parasitology

ISSN: 0031-1820

DAY: 3

MONTH: 12

YEAR: 2006

Vaccines for amoebiasis: barriers and opportunities. Information

Number of References: 46

LANGUAGE: eng

NlmUniqueID: 401121

Vaccines for amoebiasis: barriers and opportunities. Keywords Mesh Terms:

KEYWORDS: Vaccines, Synthetic

MESH TERMS: prevention & control

Chemical & Substance for Abstract: Vaccines for amoebiasis: barriers and opportunities. Information

Substance Name: Vaccines, Synthetic

Registry Number: 0

Grant and Affiliation Information for Vaccines for amoebiasis: barriers and opportunities.

AFFILIATION: Department of Medicine, Washington University School of Medicine, 660 S. Euclid Avenue, St. Louis, MO 63110, USA. sstanley@id.wustl.edu

Country: England

AGENCY: United States NIAID

GRANT: U54AI057160

ACRONYM: AI

MEDLINETA: Parasitology

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Vaccines for amoebiasis: barriers and opportunities Related Publications

• A web-based breastfeeding education program.
• Borderline personality disorder, stigma, and treatment implications.
• Cardiac energy metabolism in obesity.
• Carnitine palmitoyl transferase-I inhibition is not associated with cardiac hypertrophy in rats fed a high-fat diet.
• Chronic treatment with trimetazidine reduces the upregulation of atrial natriuretic peptide in heart failure.
• Computer simulations of Alzheimer's amyloid beta-protein folding and assembly.
• Deleterious effects of sugar and protective effects of starch on cardiac remodeling, contractile dysfunction, and mortality in response to pressure overload.
• Diabetes or peroxisome proliferator-activated receptor alpha agonist increases mitochondrial thioesterase I activity in heart.
• Diagnosis and localization of focal congenital hyperinsulinism by 18F-fluorodopa PET scan.
• Dynamic encoding of natural luminance sequences by LGN bursts.
• Elucidating amyloid beta-protein folding and assembly: A multidisciplinary approach.
• Fertilization in mouse does not require terminal galactose or N-acetylglucosamine on the zona pellucida glycans.
• High fructose diet increases mortality in hypertensive rats compared to a complex carbohydrate or high fat diet.
• Lectin-resistant CHO glycosylation mutants.
• Low carbohydrate/high-fat diet attenuates cardiac hypertrophy, remodeling, and altered gene expression in hypertension.
• Mechanisms of Disease: advances in diagnosis and treatment of hyperinsulinism in neonates.
• Numerical evaluation of the upper critical dimension of percolation in scale-free networks.
• Parallel activation of mitochondrial oxidative metabolism with increased cardiac energy expenditure is not dependent on fatty acid oxidation in pigs.
• Pombe Cdc15 homology (PCH) proteins: coordinators of membrane-cytoskeletal interactions.
• Relation between the Widom line and the breakdown of the Stokes-Einstein relation in supercooled water.
• Resistance of presynaptic CaV2.2 channels to voltage-dependent inactivation: dynamic palmitoylation and voltage sensitivity.
• Role of cellular compartmentation in the metabolic response to stress: mechanistic insights from computational models.
• Role of electrostatic interactions in amyloid beta-protein (A beta) oligomer formation: a discrete molecular dynamics study.
• Roles of O-fucose glycans in notch signaling revealed by mutant mice.
• Signal detection of salient visual features by the early visual pathway.
• Targeting pemphigus autoantibodies through their heavy-chain variable region genes.
• The threonine that carries fucose, but not fucose, is required for Cripto to facilitate Nodal signaling.
• Transcriptomic comparison of two Entamoeba histolytica strains with defined virulence phenotypes identifies new virulence factor candidates and key differences in the expression patterns of cysteine proteases, lectin light chains, and calmodulin.
• Transgenic expression of CSF-1 in CSF-1 receptor-expressing cells leads to macrophage activation, osteoporosis, and early death.
• Vaccines for amoebiasis: barriers and opportunities.